Gender, age and geographical representation over the past 50 years of schizophrenia research

Alliende, Luz María; Czepielewski, Letícia Sanguinetti; Aceituno, David; Castañeda, Carmen; Díaz, Camila; Iruretagoyena, Bárbara; Mena, Carlos; Mena, Cristián; Ramírez-Mahaluf, Juan Pablo; Tepper, Ángeles; Vasquez, Javiera; Fonseca, Laís; Machado, Vivianne; Hernández, Camilo E.; Vargas-Upegui, Cristian; Gómez-Cruz, Gladys; Kobayashi-Romero, Luis Fabián; Moncada-Habib, Tomás; Evans‐Lacko, Sara; Bressan, Rodrigo Affonseca; Gama, Clarissa Severino; López‐Jaramillo, Carlos; Fuente‐Sandoval, Camilo de la; González-Valderrama, Alfonso; Undurraga, Juan; Gadelha, Ary; Crossley, Nicolás

doi:10.1016/j.psychres.2021.114279

Cited by 4 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Available data fails to adequately account for contextual differences that influence all aspects of psychotic disorders from onset and course to outcome and system of care. Emerging literature on psychosis epidemiology in non-Western settings have been established, but the number is still not much 30 . Lack of diversity and its consequences on our understanding of etiology, phenomenology, course of illness and effect of interventions, has recently been acknowledged more.…”

Section: Discussionmentioning

confidence: 99%

ARAS recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in Iran—the cohort profile

et al. 2022

View full text Add to dashboard Cite

The Middle East is underrepresented in psychosis research. The ARAS recent onset acute phase psychosis survey (ARAS) is a longitudinal cohort across multiple centers in Iran, established to investigate characteristics, determinants and early course of psychosis in a non-Western, Middle East context. Here, baseline characteristics of the ARAS cohort are reported. The ARAS cohort enrolled patients with recent onset psychosis from September 2018 to September 2021 in East Azerbaijan, Kermanshah and Tehran, including Iranian patients from different sociocultural contexts. The baseline assessment included demographics, socioeconomic status, clinical (positive, negative, depressive symptoms) and psychosocial (religiosity, social support, self-stigma) characteristics, cognitive functioning, metabolic profile, substance use and medication use measured by validated questionnaires. These assessments will be followed up after one and five years. A total of 500 patients with a first episode of psychosis were enrolled from three provinces in Iran. With 74.1% being male, the mean age (SD) of patients was 32.3 (9.7) years. Nearly a quarter of patients was diagnosed with schizophrenia and 36.8% with substance induced psychotic disorder. Amphetamine (24%) and opium (12%) use were common, cannabis use was not (5%). Only 6.1% of patients lived alone while 29% of patients was married and had children. The majority of them had achieved secondary educational level and 34% had a paid job. The most common antipsychotic treatment was risperidone. There was a wide range for scores of PANSS, with 9.4% having dominant negative symptoms. The most common prescribed medication was risperidone. Near to 40% of patients had noticeable signs of depression and prevalence of metabolic syndrome was 13.4%. The majority of patients (57.2%) had moderate and 5.4% reported to have severe disability. More than 30% reported to be highly religious. Patients had the highest satisfaction with people living with, and the lowest for finance and job.

show abstract

Section: Discussionmentioning

confidence: 99%

ARAS recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in Iran—the cohort profile

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Women are under‐represented in psychosis research, with a recent study reporting that less than 35% of participants in over 3000 publications on Schizophrenia were women (Alliende et al., 2022). This has implications for the generalisability of the research findings and subsequent development of treatments, which is concerning given that women experience much higher rates of side effects from antipsychotic treatment compared with men (Roberts & Parry, 2023).…”

Section: Some Gaps Are Bigger Than Othersmentioning

confidence: 99%

An additional note on help‐seeking as some gaps are bigger than others: a commentary on ‘Don't mind the gap – why do we not care about the gender gap in mental health?’ Patalay and Demkowicz (2023)

McCulloch

Parry

2023

Child Adoles Ment Health

View full text Add to dashboard Cite

Sex representation in mental health research

Rosa,

Bücker

2024

European Neuropsychopharmacology

View full text Add to dashboard Cite

Gender, age and geographical representation over the past 50 years of schizophrenia research

Cited by 4 publications

References 14 publications

ARAS recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in Iran—the cohort profile

ARAS recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in Iran—the cohort profile

An additional note on help‐seeking as some gaps are bigger than others: a commentary on ‘Don't mind the gap – why do we not care about the gender gap in mental health?’ Patalay and Demkowicz (2023)

Sex representation in mental health research

Contact Info

Product

Resources

About